跳至主要内容
临床试验/NCT04544891
NCT04544891已完成不适用

Prognostic Significance of the TREM-1 Pathway Activation in COVID-19

Central Hospital, Nancy, France2 个研究点 分布在 1 个国家目标入组 830 人开始时间: 2020年10月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
830
试验地点
2
主要终点
prognostic value of the TREM-1 pathway activation on clinical worsening

研究概览

简要总结

Severe Acute Respiratory Syndrome-Corona Virus-2 infection results in a mild infection in most of the patients. However, 15-20% require hospitalization, and among them, 15-20% will develop acute respiratory failure, leading to their admission in Intensive Care Unit. There are no accepted predictive criteria for aggravation. Severe forms of Coronavirus induced disease-19 (COVID-19) are the consequence of endotheliopathy, and hyperinflammatory and pro-coagulant state. The Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) is an immunoreceptor that acts as an amplifier of the inflammatory response. TREM-1 is expressed on myeloid and endothelial cells. Its activation leads to endothelial activation and damage, hyperinflammatory, and pro-coagulant state. TREM-1 activation is associated with poor outcome during septic shock and myocardial infarction.

We here aim at investigating the relationship between TREM-1 pathway activation and clinical degradation and outcome of COVID-19 hospitalized patients.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • No consent Pregnancy protected populations

结局指标

主要结局

prognostic value of the TREM-1 pathway activation on clinical worsening

时间窗: day 28

次要结局

未报告次要终点

研究者

发起方
Central Hospital, Nancy, France
申办方类型
Other
责任方
Principal Investigator
主要研究者

Gibot Sébastien

Pr

Central Hospital, Nancy, France

研究点 (2)

Loading locations...

相似试验

TREM-1 Pathway Activation in COVID-19 | 临床试验